EP Patent

EP2457908A1 — Process for the Preparation of Compounds useful as inhibitors of SGLT

Assigned to Janssen Pharmaceutica NV · Expires 2012-05-30 · 14y expired

What this patent protects

The present invention is directed to a novel recrystallization process of a compound of formula I-S having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

USPTO Abstract

The present invention is directed to a novel recrystallization process of a compound of formula I-S having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

Drugs covered by this patent

Patent Metadata

Patent number
EP2457908A1
Jurisdiction
EP
Classification
—
Expires
2012-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.